{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:54:27Z","timestamp":1788836067359,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ijantimicag.2017.04.011","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T20:16:20Z","timestamp":1498680980000},"page":"38-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus"],"prefix":"10.1016","volume":"51","author":[{"given":"Marjan","family":"Wouthuyzen-Bakker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Tornero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant V.","family":"Nannan Panday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Jutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillem","family":"Bori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greetje A.","family":"Kampinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0010","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign body infection (FBI) study group","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/cir402","article-title":"Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus","volume":"53","author":"Senneville","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cid\/cis746","article-title":"A large multicenter study of methicillin susceptible and methicillin resistant Staphylococcus aureus prosthetic joint infections managed with implant retention","volume":"56","author":"Lora-Tamayo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0025","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0030","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1128\/AAC.01056-08","article-title":"Penetration of moxifloxacin into bone evaluated by Monte Carlo simulation","volume":"5","author":"Landersdorfer","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0035","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/jac\/dkl091","article-title":"Penetration of moxifloxacin in patients undergoing total knee arthroplasty","volume":"57","author":"Malincarne","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1179\/joc.2007.19.6.682","article-title":"Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty","volume":"19","author":"Metallidis","year":"2007","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijantimicag.2004.11.016","article-title":"Susceptibility and resistance gene to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002","volume":"25","author":"Noguchi","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0050","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1128\/JCM.00846-13","article-title":"Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis","volume":"51","author":"Bispo","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0055","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijantimicag.2008.09.011","article-title":"Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin","volume":"33","author":"Viale","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1086\/521894","article-title":"Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis","volume":"45","author":"Nijland","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0065","first-page":"979","article-title":"Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin","volume":"136","author":"Ramachandran","year":"2012","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0070","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.5588\/ijtld.14.0935","article-title":"Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study","volume":"19","author":"Manika","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0075","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1128\/AAC.00027-10","article-title":"Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections","volume":"54","author":"San Juan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0080","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1007\/s11999-011-2102-9","article-title":"New definition for periprosthetic joint infection: from the workgroup of the musculoskeletal infection society","volume":"469","author":"Parvizi","year":"2011","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0085","first-page":"e9","article-title":"KLIC-score for predicting early failure in prosthetic joint infections treated with debridement, implant retention and antibiotics","volume":"21","author":"Tornero","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0090","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1128\/AAC.45.11.3238-3241.2001","article-title":"Rifampin reduces concentrations of trimethoprim and sulfamethoxazole in serum in human immunodeficiency virus-infected patients","volume":"45","author":"Ribera","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0095","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jinf.2015.03.013","article-title":"Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination","volume":"71","author":"Bernard","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/0091270010366445","article-title":"Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism","volume":"51","author":"Gandelman","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0105","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/cid\/ciw665","article-title":"A randomized study evaluating oral fusidic acid (CEM-102) in combination with oral rifampin compared with standard-of-care antibiotics for treatment of prosthetic joint infections: a newly identified drug-drug interaction","volume":"63","author":"Pushkin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0110","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dkv481","article-title":"Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention","volume":"71","author":"Tornero","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0115","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/jac\/46.5.725","article-title":"Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC\/MIC breakpoints and equiefficient doses","volume":"46","author":"Firsov","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0120","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijantimicag.2011.03.008","article-title":"\u2018To bead or not to bead?\u2019 Treatment of osteomyelitis and prosthetic joint-associated infections with gentamicin bead chains","volume":"38","author":"Barth","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/17453674.2013.823589","article-title":"Prosthetic joint-associated infections treated with DAIR (debridement, antibiotics, irrigation, and retention): analysis of risk factors and local antibiotic carriers in 91 patients","volume":"84","author":"Kuiper","year":"2013","journal-title":"Acta Orthop"},{"key":"10.1016\/j.ijantimicag.2017.04.011_bib0130","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00264-015-2819-2","article-title":"Predictors of treatment outcome in prosthetic joint infections treated with prosthesis retention","volume":"39","author":"Puhto","year":"2015","journal-title":"Int Orthop"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T08:58:03Z","timestamp":1535705883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0924857917302108"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.04.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}